Vir Biotechnology (VIR) news
Recent news
Vir Biotechnology shares rise 1.7% on up to $1.9 bln licensing deal with Gilead
Vir Biotechnology, Inc. (NASDAQ: VIR) shares rose 1.7% following the announcement of a multi-program collaboration and licensing agreement with Gilead Sciences, Inc. (GILD), valued at up to $1.9 billion . The partnership focuses on the discovery and development of novel PRO-XTEN® dual-masked T-cell…
AInvest Wire · 1d agoVir Biotechnology shares rise 11.3% premarket on partnership with Gilead Sciences
Vir Biotechnology, Inc. (NASDAQ: VIR) shares rose 11.3% in premarket trading following news of a new partnership with Gilead Sciences, a major player in antiviral therapies. The collaboration is expected to focus on advancing Vir’s pipeline of investigational treatments for infectious diseases,…
AInvest Wire · 1d agoVir Biotechnology - Gilead to purchase 1,765,486 Vir Bio shares at $14.16 per share for $25 mln - SEC filing
AInvest Wire · 1d agoVir Biotech: Potential to receive up to $1.74B in milestones
AInvest Wire · 1d agoVir Biotech: Eligible to receive up to $135M in upfront payment
AInvest Wire · 1d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.